Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Trial Details

NCT ID

NCT07589205

Phase

PHASE1

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

• Drug: IBI3028

Locations (sample)

• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• Be able to understand and sign written informed consent to participate in this study, including all assessments and procedures specified in this pr…
• Male or female participants aged 18 years or older;
• Have histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors;
• Have at least one evaluable lesion (dose escalation) or measurable lesion (dose expansion) as per RECIST v1.1 within 28 days prior to the first dos…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.